Low-dose daily interleukin-2 immunotherapy: Accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity

AIDS

Volumn 15, Issue SUPPL. 2, 2001, Pages

  Smith, K A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cytokine; HIV; Immunotherapy; Interleukin 2; T cell immunity

Indexed keywords

CYTOKINE; RECOMBINANT INTERLEUKIN 2; VIRUS ANTIGEN; VIRUS RNA;

CELL SURVIVAL; CELLULAR IMMUNITY; CONFERENCE PAPER; CYTOKINE RELEASE; CYTOLYSIS; DOSE RESPONSE; EFFECTOR CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREACTIVITY; IMMUNOSTIMULATION; IMMUNOTHERAPY; IMMUNOTOXICITY; LYMPHOCYTE PROLIFERATION; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE; VIRUS REPLICATION;

EID: 0035090186     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200102002-00006     Document Type: Conference Paper

References (49)

1. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
2. + T cell responses associated with control of viremia
3. Cellular immune response in HIV-1 infections and effects of therapy on immunologic parameters
4. + cells in sustaining lymphocyte proliferation during lymphocytic choriomeningitis virus infection
5. + cytotoxic T-cell responses during chronic viral infection
6. + T-cell-deficient mice
7. Endogenous IL-2 contributes to T cell expansion and IFN-gamma production during lymphocytic choriomeningitis virus infection
8. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
9. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study
10. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
11. Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity
12. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection
13. Low dose daily subcutaneous interleukin 2 in combination with highly active antiretroviral therapy in HIV+ patients: A randomized, controlled trial
14. Selective in vitro growth of T lymphocytes from normal human bone marrows
15. T cell growth factor: Parameters of production and a quantitative microassay for activity
16. Heterogeneity of human T-cell growth factor(s) due to variable glycosylation
17. Production and characterization of monoclonal antibodies to human interleukin 2: Strategy and tactics
18. T cell growth factor receptors. Quantitation, specificity, and biological relevance
19. The interleukin-2 T-cell system: A new cell growth model
20. Interleukin-2: Inception, impact, and implications
21. Transient expression of interleukin 2 receptors.Consequences for T cell growth
22. Triggering the T3-Ti antigen-receptor complex results in clonal T cell proliferation through an interleukin 2-dependent autocrine pathway
23. Restoration of immunity with interleukin 2 therapy
24. + T cell proliferation. The impact of highly active antiretroviral therapy
25. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death
26. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation [see comments]
27. Implantation of IL-2-containing osmotic pump prolongs the survival of superantigenreactive T cells expanded in mice injected with bacterial superantigen
28. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors
29. IL15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation
30. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2
31. The interleukin 2 receptor
32. Cell growth signal transduction is quantal
33. The interleukin 2 receptor. Functional consequences of its bimolecular structure
34. Rational interleukin 2 therapy
35. Interleukin 2 Immunotherapy
36. HIV-1 replication is controlled at the level of T cell activation and proviral integration
37. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
38. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infedion
39. Viral dynamics of acute HIV-1 infection
40. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
41. Lowest dose interleukin-2 immunotherapy
42. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantatlon
43. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic Cancer
44. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: Prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects
45. + T cells in HIV-1infected patients receiving highly active anti-retroviral therapy
46. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
47. In vivo assessment of antiviral reactivity in chronic HIV infection
48. Immune control of HIV-1 after early treatment of acute infection